Curiox Biosystems
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Curiox Biosystems makes automated equipment and consumables for cell analysis, the laboratory process of examining and measuring cells used in biological research, drug development, and diagnostics.
Its products are supplied to researchers and scientists working in those fields. The company's core technology washes cells using natural gravity rather than a centrifuge, which it says minimises cell damage and improves reproducibility; this capability is delivered largely through software that runs on widely used liquid-handling workstations from multiple established instrument brands. Curiox is listed on KOSDAQ, South Korea's technology and small-cap stock exchange.
Summary is AI-generated and may contain errors · figures from DART filings
Its Pluto Code software is designed to run on liquid handlers from Hamilton, Tecan, Beckman Coulter, and Opentrons, making the platform hardware-agnostic across multiple established brands.
Curiox Biosystems in five facts
What does Curiox Biosystems do?
Curiox Biosystems makes automated equipment and consumables for cell analysis, the laboratory process of examining and measuring cells used in biological research, drug development, and diagnostics.
Where is Curiox Biosystems listed and in which sector?
Curiox Biosystems (Korean name: 큐리옥스바이오시스템즈) trades under KRX code 445680 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Medical Devices.
How large is Curiox Biosystems?
Its market capitalisation was US$821.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Curiox Biosystems's latest annual revenue and operating profit?
For fiscal year 2025, Curiox Biosystems reported revenue of US$3.9M, an operating loss of US$9.3M and a net loss of US$20.5M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 12.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Executives/major shareholders' securities trading planOct 2
- [Amended] Annual report (2025.12)Oct 1
- [Amended] Annual report (2024.12)Oct 1
- [Amended] Annual report (2023.12)Oct 1
- Operating results (consolidated) (preliminary) (fair disclosure)
Curiox Biosystems filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$827K (+18.07% year on year), an operating loss of US$3.13M and a net loss of US$3.4M.
Earnings · Aug 6 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Jun 29
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Curiox Biosystems reported consolidated results for FY2025: revenue of US$3.53M (+12.3% year on year), an operating loss of US$8.44M and a net loss of US$18.6M.
Earnings · Feb 5